Robert Connelly, Elicio Therapeutics CEO
Cancer vaccine developer jumps to Nasdaq via reverse merger
An IPO was off the table, but the immunotherapy experts at Elicio Therapeutics found a way to the public markets after all.
Elicio is merging …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
